There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Gilead Sciences (GILD – Research Report), Biogen (BIIB – Research Report) and Inspire Medical Systems (INSP – Research Report) with bullish sentiments.
Gilead Sciences (GILD)
In a report released today, Hartaj Singh from Oppenheimer maintained a Buy rating on Gilead Sciences, with a price target of $105.00. The company’s shares closed last Thursday at $66.16, close to its 52-week low of $65.90.
According to TipRanks.com, Singh is a 5-star analyst with an average return of
Gilead Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $85.89, a 28.2% upside from current levels. In a report issued on April 11, J.P. Morgan also maintained a Buy rating on the stock with a $95.00 price target.
See today’s best-performing stocks on TipRanks >>
Biogen (BIIB)
In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Biogen, with a price target of $270.00. The company’s shares closed last Thursday at $190.52, close to its 52-week low of $189.52.
According to TipRanks.com, Olson is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Biogen with a $285.86 average price target, a 49.1% upside from current levels. In a report issued on April 4, RBC Capital also maintained a Buy rating on the stock with a $326.00 price target.
Inspire Medical Systems (INSP)
Jefferies analyst Michael Sarcone maintained a Buy rating on Inspire Medical Systems today and set a price target of $265.00. The company’s shares closed last Thursday at $241.15.
Sarcone has an average return of
According to TipRanks.com, Sarcone is ranked #6322 out of 8786 analysts.
Inspire Medical Systems has an analyst consensus of Strong Buy, with a price target consensus of $254.85, a 5.3% upside from current levels. In a report released today, RBC Capital also initiated coverage with a Buy rating on the stock with a $285.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on GILD:
- Unusually active option classes on open April 9th
- Fly Insider: Xilio, Aerovate among weekâs notable insider trades
- Nurix Therapeutics announces extension of collaboration with Gilead
- Gilead announces FDA approval for Vemlidy sNDA
- Gilead sees FY24 EPS reduction of 3c-4c from Xilio Therapeutics deal